alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 203 Introduced in House (IH)]

<DOC>

116th CONGRESS
  1st Session
H. RES. 203

 Providing amounts for the expenses of the Committee on Armed Services 
                 in the One Hundred Sixteenth Congress.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 8, 2019

Mr. Smith of Washington (for himself and Mr. Thornberry) submitted the 
  following resolution; which was referred to the Committee on House 
                             Administration

_______________________________________________________________________

                               RESOLUTION

 
 Providing amounts for the expenses of the Committee on Armed Services 
                 in the One Hundred Sixteenth Congress.

    Resolved,

SECTION 1. AMOUNTS FOR COMMITTEE EXPENSES.

    For the expenses of the Committee on Armed Services (hereafter in 
this resolution referred to as the ``Committee''), including the 
expenses of all staff salaries, there shall be paid, out of the 
applicable accounts of the House of Representatives for committee 
salaries and expenses, not more than $17,741,102 for the One Hundred 
Sixteenth Congress.

SEC. 2. SESSION LIMITATIONS.

    Of the amount specified in section 1--
            (1) not more than $8,535,980 shall be available for 
        expenses incurred during the period beginning at noon on 
        January 3, 2019, and ending immediately before noon on January 
        3, 2020; and
            (2) not more than $9,205,122 shall be available for 
        expenses incurred during the period beginning at noon on 
        January 3, 2020, and ending immediately before noon on January 
        3, 2021.

SEC. 3. VOUCHERS.

    Payments under this resolution shall be made on vouchers authorized 
by the Committee, signed by the Chairman of the Committee, and approved 
in the manner directed by the Committee on House Administration.

SEC. 4. REGULATIONS.

    Amounts made available under this resolution shall be expended in 
accordance with regulations prescribed by the Committee on House 
Administration.
                                 <all>
```
Exhibit 32

Written Statement of
the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. s.1350

Solely for the purposes of complying
with 18 U.S.C. s.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, we, the undersigned President and Chief Executive Officer and the Chief Financial
Officer of Banta Corporation (the Corporation), hereby certify, based on our
knowledge, that the Annual Report on Form 10-K of the Corporation for the year ended
January 3, 2004 (the Report) fully complies with the requirements of Section
13(a) of the Securities Exchange Act of 1934 and that information contained in the Report
fairly presents, in all material respects, the financial condition and results of
operations of the Corporation.

| | /s/ Stephanie A. Streeter            
| | -------------------------------------
| | Stephanie A. Streeter                
| | President and Chief Executive Officer
| | /s/ Geoffrey J. Hibner               
| | Geoffrey J. Hibner                   
| | Chief Financial Officer              
| | March 18, 2004                       
| | Date
---

Exhibit 32.1

CERTIFICATIONS PURSUANT TO SECTION 906 OFTHE
SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of mPhase Technologies,
Inc., a New Jersey corporation (the "Company"), on Amendment No. 7 to Form 10Q/A for the quarter
ended December 31, 2009 as filed with the Securities and Exchange Commission
(the "Report"), I, Ronald A. Durando, Chief Executive Officer of the Company
certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18U.S.C.
Section 1350), that to his knowledge:

|1. | The Report fully complies with the requirements of
      Section 13(a) or 15(d) of the Securities Exchange Act of 1934;
  and                                   
|-- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                 
|2. | The information contained in the Report fairly presents,
      in all material respects, the financial condition and results of
      operations of the Company.

/s/ Ronald A.
DurandoRonald A. Durando Chief Executive Officer

February 11, 2011

---
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Small Business Administration

          - [Disaster Declaration #11750 and #11751]

# AGENCY:

U.S. Small Business Administration.

# ACTION:

Amendment 3.

# SUMMARY:

This is an amendment of the Presidential declaration of a major disaster for the State of West Virginia (FEMA-1838-DR), dated 05/15/2009.

*Incident:*                         Severe Storms, Flooding, Mudslides, and Landslides.                    

*Incident Period:*                         05/03/2009 through 06/08/2009.                    

# 

*Effective Date:*                         06/12/2009.                    

*Physical Loan Application Deadline Date:*                         07/14/2009.                    

*EIDL Loan Application Deadline Date:*                         02/15/2010.                    

# ADDRESSES:

Submit completed loan applications to: U.S. Small Business Administration, Processing And Disbursement Center, 14925 Kingsport Road, Fort Worth, TX 76155.

# FOR FURTHER INFORMATION CONTACT:

A. Escobar, Office of Disaster Assistance, U.S. Small Business Administration, 409 3rd Street, SW., Suite 6050, Washington, DC 20416.

# SUPPLEMENTARY INFORMATION:

                    The notice of the Presidential disaster declaration                           ( print page 29249)                        for the State of West Virginia, dated 05/15/2009 is hereby amended to include the following areas as adversely affected by the disaster:                

*Primary Counties:*                     (Physical Damage and Economic Injury Loans): Calhoun.                

*Contiguous Counties: (Economic Injury Loans Only):*

West Virginia: Braxton, Clay, Gilmer, Ritchie, Roane, Wirt.

All other information in the original declaration remains unchanged.

(Catalog of Federal Domestic Assistance Numbers 59002 and 59008)

James E. Rivera,

Acting Associate Administrator for Disaster Assistance.

[FR Doc. E9-14368 Filed 6-18-09; 8:45 am]

BILLING CODE 8025-01-P
,, 1 

# qoq -03**'::£_~:7.-<146-r** 

# _ ......**-------~--:** 

# _______**~** 

# __**;J-'8::_~ot5** ___

## ~~-**--==:J.e~ Gut;(~~~~**  

# .. ··--·**---~---------** 

# --**_flta~_,** 

### __ 

## JjG_

______ Z8:21

### (_:-__~-32~------ . _

### -~--~----

-----**-----~------------**

-------,----· -----------**---~------------------** --------------------------------**RECEIVEDIN-------------~-----=----- ---.-----------~----** 

_______________ ,._·**~l~~~** SF"**C21MIN_~~** APPEALS

_**·-----~-------.** _______ _

..

;**--~--------_:_** _______ _fE_ItLl 2Jll5__

_______________**----·-------------~-** _ Abel**Acos~a,** Clerk
<PAGE>
                                                                    EXHIBIT 32.1


                             BKF CAPITAL GROUP, INC.

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

     In connection with the Annual Report of BKF Capital Group, Inc. (the
"Company") on Form 10-K for the period ending December 31, 2005 as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), I,
John C. Siciliano, Chief Executive Officer of the Company, certify, pursuant to
18 U.S.C. Section 1350 (including subsections (a) (b) and (c) thereof), as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

          (1) The Report fully complies with the requirements of section 13(a)
     or 15(d) of the Securities Exchange Act of 1934; and

          (2) The information contained in the Report fairly presents, in all
     material respects, the financial condition and results of operations of the
     Company.

                                                       /s/ JOHN C. SICILIANO
                                                      -----------------------
                                                          John C. Siciliano
                                                      Chief Executive Officer

March 16, 2006
#### In the Matter of the Claim of Patricia Keane, Appellant. Commissioner of Labor, Respondent.

Submitted February 19, 2013;

decided April 25, 2013

Motion for reargument of motion for leave to appeal denied *[see*20 NY3d 854 (2012)].

Judge Rivera taking no part.
EXHIBIT 21.0**Subsidiaries of Registrant**All subsidiaries are wholly owned unless otherwise stated below:2 Quaker Road, Inc., a New York Corporation 2 Quaker Road, LLC, a Delaware Limited Liability Company 265 Livingston Street Corp., a New Jersey Corporation Barr Distribution Company, a Delaware Corporation Barr Laboratories, Inc., a Delaware Corporation Barr Ventures, LLC. a Delaware Limited Liability Company BMI, Inc., a Delaware Corporation BRL, Inc., a Delaware Corporation Duramed Pharmaceuticals, Inc., a Delaware Corporation Duramed Pharmaceutical Sales Corp., a Delaware Corporation Duramed Research, Inc., a Delaware Corporation Women’s Capital Corp., a Delaware Corporation Copper 380T LLC, a Delaware Limited Liability Company Barr Laboratories Europe B.V. Barr International Services, Inc Barr East Hanover Services, IncPLIVA d.d., Zagreb, CroatiaPLIVA HRVATSKA d.o.o., Zagreb, Croatia **•** PLIVA s.r.o., Bratislava, SlovakiaPLIVA—ISTRAŽIVANJE  I RAZVOJ d.o.o., Zagreb, CroatiaVETERINA d.o.o., Kalinovica, Croatia **•** VETERINA POLSKA Sp. z.o.o., Krakow, Poland  **•** VETERINA PLUS, d.o.o., Ljubljana, SloveniaPLIVA ZDRAVLJE d.o.o., Zagreb, CroatiaPLIVA ESOP d.o.o., Zagreb, CroatiaPHARMAING d.o.o., Zagreb, CroatiaPUNCTUM STUDIO d.o.o., Zagreb, CroatiaGLOBALNI POSLOVNI SERVISI-IT d.o.o., Zagreb, CroatiaPLIVA London Ltd., Petersfield, UKPLIVA USA INCORPORATED, New York, USAPLIVA Ljubljana d.o.o., Ljubljana, SloveniaPLIVA Sarajevo d.o.o., Sarajevo, Bosnia and HerzegovinaPLIVA Skopje d.o.o.e.l., Skopje, The Former Yugoslav Republic of MacedoniaPLIVA RUS Ltd., Moscow, Russian FederationPLIVA Pharma UK Ltd, Petersfield, UK **•** PLIVA Pharma Ltd., Petersfield, UKPLIVA Pharma Holding B.V., Amsterdam, Netherlands **•** PLIVA Pharma S.p.A., Milan, Italy  **•** PLIVA Pharma SAS, Paris, France  **•** PLIVA Pharma Iberia S.A., Madrid, Spain **•** Laboratories Edigen, S.A., Madrid, Spain **•** Uso Rational. S.A., Madrid, Spain  **•** PLIVA Pharma GmbH, Mannheim-Feudenheim, Germany  **•** PLIVA Finance B.V., Amsterdam, Netherlands  **•** PLIVA-Lachema a.s., Brno, Czech Republic (96.93%)
1

 
 **•** LACHEMA s.r.o., Brno, Czech Republic  **•** PLIVA-LACHEMA Diagnostika s.r.o., Brno, Czech Republic **•** Lachema International, Puscino, Russian Federation (80%),  **•** PLIVA s.r.o., Prague, Czech Republic**•** AWD.pharma Beteiligungs-GmbH, Dresden, Germany **•** AWD.pharma GmbH & Co.KG, Dresden, Germany **•** AWD PHARMA Sp.z.o.o., Warsaw, Poland  **•** ACCEDO Arzneimittel GmbH, Dresden, Germany  **•** AWD.pharma Spol. s.r.o. v likvidacii, Bratislava,Slovakia **•** SIA PLIVA, Riga, Latvia **•** UAB PLIVA, Vilnius, Lithuania **•** PLIVA Hungaria Kft., Budapest, Hungary  **•** PLIVA KRAKOW S.A., Krakow, Poland (96,79%) **•** PLIVA Research India Private Ltd., Goa, IndiaPharmazug AG, Zug, Switzerland **•** PLIVA International AG, Zug, Switzerland  **•** EUROPHARMA d.o.o., Zagreb, CroatiaPLIVA Global Finance AG, Zug, Switzerland**•** PAM Kft., Szombathely, Hungary **•** PROPERTY ASSET MANAGEMENT USA Inc, New York, USA **•** PLIVA Inc., East Hanover, USA **•** Odyssey Pharmaceuticals Inc., Delaware, USA
2
#### Radhika Lila, Appellant, v Juan Bata et al., Respondents.

[822 NYS2d 781]

In an action to recover damages for personal injuries, the plaintiff appeals from a judgment of the Supreme Court, Queens County (Huttner, J.), entered June 29, 2005, which is in favor of the defendants and against her dismissing the complaint.

Ordered that the judgment is reversed, on the law and in the exercise of discretion, the complaint is reinstated, and the matter is remitted to the Supreme Court, Queens County, for a trial on the issue of damages, with costs to abide the event.

The Supreme Court improvidently exercised its discretion in denying the plaintiffs application for a brief continuance of the trial on the issue of damages due to the unavailability of her expert doctor. The expert’s testimony was material and there is no indication in the record that the request for a continuance was made for the purpose of delay, or that the need for a continuance resulted from the plaintiffs failure to exercise due diligence *(see Zysk v Bley,*24 AD3d 757, 758 [2005]; *Hodges v City of New York,*22 AD3d 525, 526-527 [2005]; *Byrnes v Varlack,*17 AD3d 616, 616-617 [2005]; *Wai Ming Ng v Tow,*260 AD2d 574, 574 [1999]; *Romero v City of New York,*260 AD2d 461, 461-462 [1999]). Florio, J.E, Crane, Luciano, Spolzino and Covello, JJ., concur.
II 

111TH CONGRESS 

2D SESSION S. 3503 

To authorize grants for an international documentary exchange program. 

IN THE SENATE OF THE UNITED STATES 

JUNE 17, 2010 

Mr. CARDIN introduced the following bill; which was read twice and referred 

to the Committee on Foreign Relations 

A BILL 

To authorize grants for an international documentary 

exchange program. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘International Docu5 mentary Exchange Act of 2010’’. 

6 SEC. 2. GRANTS FOR INTERNATIONAL DOCUMENTARY EX7 CHANGE PROGRAMS. 

8 (a) ASSISTANCE.—The Secretary of State may award 

9 grants, on such terms and conditions as the Secretary may 

10 determine, to United States film makers and nongovern11 mental organizations that use independently produced 


tjames on DSKG8SOYB1PROD with BILLS
2 

•S 3503 IS

1 documentary films to promote better understanding of the 

2 United States among individuals in other countries. 

3 (b) USE OF GRANT FUNDS.—Grants awarded under 

4 subsection (a) shall, to the maximum extent practicable, 

5 be used— 

6 (1) to fund, distribute, and promote documen7 tary films that convey a diversity of views about life 

8 in the United States to foreign audiences; 

9 (2) to support the production of documentaries 

10 described in paragraph (1) that are made by inde11 pendent foreign and domestic producers, selected 

12 through a peer review process; and 

13 (3) to develop a network of overseas partners to 

14 produce, distribute, and broadcast such documen15 taries according to the allowable rights of each pro16 gram. 

17 (c) PREFERENCE FACTORS.—In awarding grants 

18 under this section, the Secretary shall give preference to 

19 nongovernmental organizations that— 

20 (1) are as cost effective as possible; and 

21 (2) have experience supporting independently 

22 produced documentary films. 

23 (d) REPORT.—Not later than 2 years after the date 

24 of the enactment of this Act, the Secretary shall submit 


tjames on DSKG8SOYB1PROD with BILLS
3 

•S 3503 IS

1 a report to Congress that describes in detail the implemen2 tation of this section. 

3 (e) AUTHORIZATION OF APPROPRIATIONS.—There is 

4 authorized to be appropriated to the Secretary of State 

5 such sums as may be necessary for each of fiscal years 

6 2010 and 2011 to carry out this section. 

Æ 


tjames on DSKG8SOYB1PROD with BILLS
IV 

116TH CONGRESS 

1ST SESSION H. RES. 188 

Expressing support for designation of July as National Sarcoma Awareness 

Month. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 7, 2019 

Mr. DUFFY (for himself and Ms. JACKSON LEE) submitted the following 

resolution; which was referred to the Committee on Oversight and Reform 

RESOLUTION 

Expressing support for designation of July as National 

Sarcoma Awareness Month. 

Whereas sarcoma is a cancer of connective tissues, such as 

nerves, muscles, joints, fat, bones, and blood vessels, and 

it can arise anywhere in the body; 

Whereas 15,000 people in the United States were diagnosed 

with sarcoma last year, more than 6,000 died, and 

50,000 are struggling with the disease at any one time; 

Whereas 1 percent of cancers diagnosed in adults and 20 percent of cancers diagnosed in children each year are sarcoma; 

Whereas more than 50 subtypes of sarcoma have been identified; 


pamtmann on DSKBFK8HB2PROD with BILLS
2 

•HRES 188 IH 

Whereas the National Cancer Institute recognizes that sarcoma is often misdiagnosed and underreported; and 

Whereas July would be an appropriate month to designate as 

National Sarcoma Awareness Month to raise awareness 

of the disease and encourage more individuals to get 

properly diagnosed and treated: Now, therefore, be it 

1 Resolved, That the House of Representatives supports 

2 the designation of National Sarcoma Awareness Month. 

Æ 


pamtmann on DSKBFK8HB2PROD with BILLS
CONSENT OF INDEPENDENT ACCOUNTANT



Board of Directors
Badger Paper Mills, Inc. and Subsidiaries

We have issued our reports dated February 1, 2000, accompanying the consolidated
financial  statements  and  schedules  incorporated  by  reference in the Annual
Report of Badger Paper Mills,  Inc. and  Subsidiaries on Form 10-K for the years
ended December 31, 1999,  1998 and 1997. We hereby consent to the  incorporation
by  reference  of said reports in the  Registration  Statements  of Badger Paper
Mills, Inc. and Subsidiaries on Forms S-8 (File No.  333-01671,  effective March
13, 1996 and File No. 333-01673, effective March 13, 1996).



/s/ Grant Thornton LLP

Appleton, Wisconsin
March 21, 2000
United States Court of Appeals

for the Fifth Circuit ____________

No. 23-50216

Summary Calendar

____________

United States of America, 

Plaintiff—Appellee,

versus

Miguel Camarena, 

Defendant—Appellant.

______________________________

Appeal from the United States District Court 

for the Western District of Texas

USDC No. 6:07-CR-158-4

______________________________

Before Elrod, Oldham, and Wilson, Circuit Judges.

Per Curiam:*

Miguel Camarena, federal prisoner # 37223-177, appeals the district 

court’s denial of his motion for compassionate release, filed pursuant to 18 

U.S.C. § 3582(c)(1)(A)(i). On appeal, he raises three arguments: (1) the 

district court erred when it did not find his purported sentencing errors to be 

extraordinary and compelling reasons warranting a reduced sentence; (2) the 

_____________________

* This opinion is not designated for publication. See 5th Cir. R. 47.5.

United States Court of Appeals

Fifth Circuit

FILED

December 8, 2023

Lyle W. Cayce

Clerk

Case: 23-50216 Document: 00516995615 Page: 1 Date Filed: 12/08/2023
No. 23-50216

2

district court erred in determining that the 18 U.S.C. § 3553(a) factors did 

not support a sentence reduction; and (3) the district court did not provide 

adequate reasons in its order denying his motion, thus violating his due 

process rights. Camarena has filed a motion for leave to file an out-of-time 

reply brief, and we GRANT the motion. Accordingly, we have considered 

Camarena’s reply brief. 

We review for abuse of discretion. See United States v. Chambliss, 948 

F.3d 691, 693 (5th Cir. 2020). As we have previously held, when a district 

court denies a motion for compassionate release, it must give ‘“specific 

factual reasons’ for its decision.” United States v. Handlon, 53 F.4th 348, 351 

(5th Cir. 2022) (quoting Chambliss, 948 F.3d at 693). Therefore, a district 

court must explain its analysis of the § 3553 factors. United States v. Stanford, 

79 F.4th 461, 464 (5th Cir. 2023). 

Here, the district court concluded that the § 3553(a) factors did not 

warrant relief; specifically, the court cited the nature and circumstances of 

Camarena’s offense of conviction and the need for the sentence to reflect the 

seriousness of his offense, promote respect for the law, provide just 

punishment, adequately deter criminal conduct, and protect the public from 

his further crimes. See § 3553(a)(1), (2)(A)–(C). We hold that this analysis 

is sufficient for due process purposes. 

Although Camarena disagrees with the district court’s weighing of the 

§ 3553(a) factors, his disagreement is not a sufficient ground for reversal. See 

Chambliss, 948 F.3d at 694. Because the district court’s assessment of the 

§ 3553(a) factors supports the denial of Camarena’s motion, we do not reach 

his argument that the court erred in finding that he did not establish his 

extraordinary and compelling reasons for compassionate release. See id. at 

693–94. 

AFFIRMED. 

Case: 23-50216 Document: 00516995615 Page: 2 Date Filed: 12/08/2023